SAN FRANCISCO, Sept. 20, 2022 (GLOBE NEWSWIRE) —
ProLynx, Inc., a biotechnology company with novel platform technology for treatment half-life extension, enabling the development of new and potentially best-in-class treatments, today announced that Richard King, MBA, was appointed Managing Director and as a member of the Board of Directors. Additionally, Chris Ehrlich, MBA, has joined the company as a member of the Board of Directors.
“As a seasoned industry executive with a track record of partnering success, Richard is a great fit for ProLynx,” said ProLynx Board Member Bill Rutter. “The ProLynx Board of Directors looks forward to working with Richard and the management team to realize the promise of our innovative technology for improving the lives of patients and caregivers. Additionally, I am delighted to welcome Chris to the Board. His expertise in venture capital, business development and financing strengthens the capabilities of our board.
Richard King is an accomplished executive with over 35 years of leadership experience in the biotechnology and pharmaceutical industries. He has raised over $1 billion in private and public capital, completed several business transactions including the sale of Tercica, Inc., the partnership of AcelRx and Grunenthal on a novel pain management system, and the CALIBR’s strategic affiliation with the Scripps Research Institute. .
“I am thrilled to be joining ProLynx at this time,” said Richard King. “ProLynx technology is incredibly unique in extending the half-life of proteins, peptides and small molecules. This advance may make existing drugs more effective, better tolerated and require less frequent administration. ProLynx technology can also be applied to molecules in development that may otherwise never be advanced due to efficacy or toxicity concerns, allowing these product candidates to move forward and eventually become game-changing treatments. the lives of patients.
Chris Ehrlich began his career at the consulting firm LEK before becoming a business development manager in the pharmaceutical industry. Subsequently, he was managing director of the venture capital firm InterWest, serving on the board of several companies. He joined Locust Walk, a life science transactions firm, where as Global Head of Biotechnology and Head of Strategic Transactions, he researched and led several transactions for emerging biopharmaceutical companies.
“ProLynx is in an excellent position with its lead development program in clinical trials to treat various cancers, as well as several other programs that have demonstrated proof of concept in a variety of disease areas,” said Chris Ehrlich. “I’m excited to join the board of directors to help drive this new half-life extension technology forward to advance treatment options for patients in need.”
ProLynx is a San Francisco, California-based biotechnology company that develops proprietary drug delivery technologies to extend the half-life of treatments. The ProLynx pipeline is centered on a long-acting oncology drug, PLX038, in phase 2 clinical trials, a long-acting interleukin 15, PLX015, for immuno-oncology and a very long-acting C-type natriuretic peptide, PLX138 , for achondroplasia, as well as several other starter programs.